Back

Disparities in SGLT2i utilization among heart failure patients with different ejection fraction in China: findings from chinese cardiovascular association database-heart failure center registry

1 September 2024 (10:00 - 10:40)
Organised by: Logo
Congress Presentation Part of: Understanding the effects and utilisation of SGLT2 inhibitors in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Qixian Zhang

Peking University First Hospital, Beijing (China)

5 More presentations in this session

Presentation thumbnail
Effect of Dapagliflozin on health-related quality of life in patients with heart failure: a meta-analysis of Randomized Controlled Trials
Mrs M. De Souza (Curitiba, BR)
Abstract Slides Video
Presentation thumbnail
Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure
Mr A. Hacil (Paris, FR) Professor O. Hanon (Paris, FR)
Abstract Slides Video
Presentation thumbnail
The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease
Mrs O. Obertynska (Vinnitsa, UA)
Abstract Slides Video
Presentation thumbnail
Impact of dapagliflozin on supraventricular and ventricular arrhythmias, assessed by Holter ECG, in patients with heart failure with reduced ejection fraction
Professor A. ABDELLAH (Ismailia, EG)
Abstract Slides Video
Presentation thumbnail
Beneficial effects of the SGLT2 inhibition on oxidative skeletal muscle in infarcted rats
Miss L. Souza (Botucatu, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Understanding the effects and utilisation of SGLT2 inhibitors in heart failure

The Event

Event poster

ESC Congress 2024

1 September 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Description of the profile of the patient with heart failure depending on the discharge service and the possible optimization of treatment with SGLT2i in a retrospective cohort from 2021 to 2022
thumbnail
Congress Presentation
Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation
thumbnail
Congress Presentation
Sodium-glucose co-transporter-2 inhibitors: prognostic benefit in real-world, elderly, comorbid HFmrEF and HFpEF patients

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources